Damora Therapeutics, Inc. Common Stock (DMRA) Projected to Announce Quarterly Earnings on Wednesday

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) is expected to be issuing its Q2 2026 resultson Wednesday, August 5th. Analysts expect the company to announce earnings of ($0.4470) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Monday, August 10, 2026 at 4:00 PM ET.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.23). On average, analysts expect Damora Therapeutics, Inc. Common Stock to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Damora Therapeutics, Inc. Common Stock Price Performance

Shares of Damora Therapeutics, Inc. Common Stock stock opened at $28.99 on Monday. The stock has a market cap of $1.78 billion, a price-to-earnings ratio of -5.20 and a beta of 1.47. The firm’s 50-day moving average is $26.00 and its two-hundred day moving average is $26.09. Damora Therapeutics, Inc. Common Stock has a 1 year low of $2.45 and a 1 year high of $38.33.

Hedge Funds Weigh In On Damora Therapeutics, Inc. Common Stock

Several institutional investors and hedge funds have recently bought and sold shares of DMRA. Janus Henderson Group PLC acquired a new stake in Damora Therapeutics, Inc. Common Stock in the 4th quarter worth approximately $40,000. Virtu Financial LLC acquired a new position in Damora Therapeutics, Inc. Common Stock during the 3rd quarter valued at approximately $49,000. Connective Capital Management LLC acquired a new position in Damora Therapeutics, Inc. Common Stock during the 3rd quarter valued at approximately $100,000. Geode Capital Management LLC purchased a new position in shares of Damora Therapeutics, Inc. Common Stock in the fourth quarter worth $266,000. Finally, Boothbay Fund Management LLC purchased a new position in shares of Damora Therapeutics, Inc. Common Stock in the fourth quarter worth $2,204,000. 14.20% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. TD Cowen started coverage on shares of Damora Therapeutics, Inc. Common Stock in a research note on Monday, June 8th. They set a “buy” rating on the stock. Royal Bank Of Canada began coverage on shares of Damora Therapeutics, Inc. Common Stock in a research note on Friday, April 24th. They issued an “outperform” rating and a $40.00 price objective for the company. HC Wainwright restated a “buy” rating and set a $45.00 target price on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday, July 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research report on Thursday, June 18th. Finally, Wedbush lifted their price target on Damora Therapeutics, Inc. Common Stock from $35.00 to $40.00 and gave the company an “outperform” rating in a report on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $44.00.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto Inc is a clinical?stage biotechnology company developing small?molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin?3, an extracellular carbohydrate?binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase?like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin?3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin?3 inhibitor being evaluated for systemic fibrotic disorders.